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Abstract
Background: To address human resource and infrastructure shortages, resource-constrained countries are being
encouraged to shift HIV care to lesser trained care providers and lower level health care facilities. This study evaluated
the cost-effectiveness of down-referring stable antiretroviral therapy (ART) patients from a doctor-managed, hospital-based
ART clinic to a nurse-managed primary health care facility in Johannesburg, South Africa.
Methods and Findings: Criteria for down-referral were stable ART ($11 mo), undetectable viral load within the previous
10 mo, CD4.200 cells/mm
3, ,5% weight loss over the last three visits, and no opportunistic infections. All patients down-
referred from the treatment-initiation site to the down-referral site between 1 February 2008 and 1 January 2009 were
compared to a matched sample of patients eligible for down-referral but not down-referred. Outcomes were assigned
based on vital and health status 12 mo after down-referral eligibility and the average cost per outcome estimated from
patient medical record data. The down-referral site (n=712) experienced less death and loss to follow up than the
treatment-initiation site (n=2,136) (1.7% versus 6.2%, relative risk=0.27, 95% CI 0.15–0.49). The average cost per patient-
year for those in care and responding at 12 mo was US$492 for down-referred patients and US$551 for patients remaining
at the treatment-initiation site (p,0.0001), a savings of 11%. Down-referral was the cost-effective strategy for eligible
patients.
Conclusions: Twelve-month outcomes of stable ART patients who are down-referred to a primary health clinic are as good
as, or better than, the outcomes of similar patients who are maintained at a hospital-based ART clinic. The cost of treatment
with down-referral is lower across all outcomes and would save 11% for patients who remain in care and respond to
treatment. These results suggest that this strategy would increase treatment capacity and conserve resources without
compromising patient outcomes.
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The rapid expansion of large-scale provision of care and
treatment for HIV/AIDS in sub-Saharan Africa has placed
tremendous pressure on the region’s human resources. As a result,
the World Health Organization, other international agencies, and
national governments are actively encouraging the shifting of
clinical care responsibilities to lesser trained, less expensive, and
generally less scarce cadres of the clinical workforce [1].
In South Africa, a major component of this ‘‘task shifting’’
strategy is to reduce the role of doctors in managing patients on
antiretroviral therapy (ART), in favor of primary health care
nurses (PHCNs). Unlike in many countries in the region, South
Africa’s national treatment program has been largely managed by
doctors. Nurses have not been authorized to dispense antiretro-
viral drugs (ARVs), initiate patients on treatment, or conduct
medical examinations in lieu of doctors. The number of accredited
sites authorized to provide ART has thus been limited by the
availability of doctors. Since most primary health care facilities are
staffed entirely by nurses, most accredited ART sites have been
located at hospitals rather than primary care clinics.
There is a small but expanding body of evidence from sub-
Saharan Africa demonstrating that nurses managing ART patients
at primary health care facilities can achieve very good outcomes. A
recent systematic review of task-shifting in Africa identified seven
cohort studies of nurse-initiated and/or nurse-managed adult
treatment [2]. Those that reported outcomes generally showed
nurses achieved comparable or superior results to doctor-led
treatment in the same general setting, but only one undertook a
direct comparison of doctor-managed versus nurse-managed
treatment of similar patient populations [3]. Primary health care
facilities achieved better outcomes than hospitals in a recent study
from South Africa, but patients were treated by doctors at both
levels [4]. A prospective controlled evaluation in Swaziland found
equally good outcomes amongst stable HIV patients managed by
nurses in a primary care facility compared to those receiving
routine hospital care [5]. Malawi has shown similar success in
decentralizing care and allowing non-physician clinicians to
initiate ART [6]. In Kenya a clinical trial evaluated whether the
ART management could be partially shifted from health care
workers to persons living with HIV/AIDS who would monitor
patients within the community [7]. This showed similar clinical
outcomes but with fewer clinic visits. No studies have estimated the
cost differences between the two approaches using primary data.
In 2010, the South African government revised its HIV
treatment guidelines for the first time since the program launched
in 2004. Among a host of changes to drug regimens, eligibility
criteria, and monitoring protocols, the revised guidelines included
the following two objectives: to ‘‘enable nurses to initiate ARVs for
treatment and prevention’’ and to ‘‘enable primary health care
facilities to initiate, manage, monitor, and refer patients.’’
Justification for this change included a recently published
randomized trial set in South Africa demonstrating that, under
the carefully regulated conditions of a clinical trial, patients
initiated on ART by doctors, but monitored by nurses, at primary
health care clinics achieved similar treatment outcomes as those
managed solely by doctors [8].
Prior to the 2010 guideline revision, a number of interventions
to shift treatment delivery to lower level facilities and from doctors
to nurses had already been piloted in routine care settings. Among
these was a strategy of ‘‘down referring’’ stable, adult ART
patients from a central hospital to nearby primary clinics—the
same strategy tested by the randomized clinical trial in South
Africa, but in a routine care setting—pioneered by the Gauteng
Province Department of Health and Right to Care, a South
African nongovernmental organization supported primarily by the
United States President’s Emergency Plan for AIDS Relief. To
evaluate the implications of this down-referral strategy for
treatment outcomes and costs, we conducted a cost-effectiveness
analysis of the treatment program at the Themba Lethu Clinic in
Johannesburg and a nearby primary health clinic serving as a
down-referral site.
Methods
Ethics Statement
The University of the Witwatersrand and Boston University
provided ethical approval of the study. In order to protect the
anonymity of the patients, the study was conducted as an unlinked,
retrospective analysis of a patient data set that did not contain any
individual identifiers.
Down-Referral Procedures
Under the down-referral strategy evaluated in this study, all
patients receive pre-ART care and initiate ART at an accredited,
hospital-based HIV/AIDS clinic, which we will refer to as the
treatment-initiation site. For patients who are eligible for and
accept down-referral, management of their care is moved to a
down-referral site, which is a primary health clinic (PHC). PHCs
typically provide reproductive, maternal, and child health care,
TB treatment, HIV testing, and other basic services but are not
typically accredited to provide ART.
To be eligible for down-referral, patients must have been on
ART for at least 11 mo; they must have no opportunistic
infections, a CD4 cell count .200 cells/mm
3, and a stable weight
as reflected by ,5% weight loss between the last three visits; and
their latest HIV viral load within the last 10 mo must be
undetectable (,400 copies/ml). The treatment-initiation site
involved in this study performs the first routine viral load test
after 4 mo on treatment, and the second at 10 mo, establishing the
time intervals used in the down-referral criteria. Treatment-
initiation site patients who meet these criteria are invited (but not
required) to transfer to a down-referral site. For those who accept
down-referral, the treatment-initiation site doctor then writes a
prescription for 6 mo of ARVs. Down-referred patients are
dispensed a 2-mo supply of ARVs at the treatment-initiation site
and make an appointment at the down-referral site for 2 mo later.
All subsequent ARV pickups occur at the down-referral site. At
both the treatment-initiation and down-referral sites, stable
patients are scheduled for medication pickups every 2 mo.
Treatment follows South African national guidelines, which
during the study period called for a first-line regimen of stavudine,
lamivudine, and nevirapine or efavirenz and routine CD4 counts
and viral load tests every 6 mo.
The main difference between the routine monitoring conducted
at the down-referral site and the treatment-initiation site is the
cadre of clinical staff involved. While the treatment-initiation site
relies on medical consultations with doctors, patients at the down-
referral site see only PHCNs, professional nurses with a
qualification in primary health care. Down-referred patients have
a nurse consultation at every routine visit (every 2 mo), while
patients at the treatment-initiation site have a doctor consultation
only every 6 mo. At each visit, the PHCN asks whether the patient
has had any unexplained weight loss, experienced symptoms
related to hyperlactatemia, and/or visited any other medical
facility since the last appointment. If none of these events has
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scheduled for an appointment 2 mo later. Otherwise, if any of
these events has occurred, the PHCN conducts a full consultation.
The PHCN may prescribe or change non-ARV medications and
renew existing ARV prescriptions but cannot alter the patient’s
original ARV prescription. After a full consultation, the PHCN
can continue the patient on the standard drug collection and visit
schedule (i.e., every 2 mo), treat the patient and request a follow-
up visit before the next scheduled visit, or up-refer (return) the
patient to the treatment-initiation site. The PHCN also does a
routine blood draw 4 mo into each 6-mo prescription cycle, with
samples processed for viral load, CD4 count, full blood count,
alanine aminotransferase, aspartate aminotransferase, and, de-
pending on drug regimen, cholesterol, triglycerides, creatinine,
and/or lactates. Based on the results of these tests, the PHCN can
renew the patient’s ARV prescription for another 6 mo, change
any concomitant non-ARV medications, draw blood again to
confirm the laboratory findings, and/or up-refer the patient
immediately. Both sites performed the same routine monitoring
tests every 6 mo, but doctors at the treatment-initiation site were
allowed to order additional laboratory tests if required, whereas
nurses at the down-referral site had a restricted list of laboratory
tests available and had to up-refer a patient if non-routine tests
were indicated.
Patients who are up-referred to the treatment-initiation site
remain under treatment-initiation site care until a treatment-
initiation site doctor recommends (re-)down-referral. At both sites,
a patient who is more than 3 mo late for the next scheduled visit is
classified as lost to follow up.
Study Sites
The treatment-initiation site in this study is the Themba Lethu
Clinic (TLC) of Helen Joseph Hospital in Johannesburg, a large
public sector ART clinic at a secondary hospital. The site, which
has been described in detail elsewhere [9], started providing ART
in April 2004 and has since initiated more than 18,500 patients on
treatment. Treatment is initiated and managed by doctors, as
required by the treatment guidelines in place in South Africa until
2010. The clinic is sponsored by the Gauteng Province
Department of Health, with additional support from the United
States President’s Emergency Plan for AIDS Relief.
Due to increasing patient numbers and shortages of human,
financial, and infrastructural resources, TLC began down-
referring to PHCs within its patient catchment area in 2008. Its
first down-referral site was Crosby Clinic, a PHC of the City of
Johannesburg roughly 3 km from TLC. Crosby Clinic established
a down-referral wing that has its own ART waiting area,
consultation rooms, and pharmacy and operates independently
of other PHC departments. It can therefore be closely integrated
with the treatment-initiation site and avoid the long patient
waiting times that are characteristic of many PHC facilities.
Because it is located near the treatment-initiation site, patient
transport costs are similar between the two facilities.
The treatment-initiation and down-referral sites make use of the
same electronic patient management and data system, Therapy
Edge-HIV. The system transfers patient records between the
treatment-initiation and down-referral sites when a patient is
down- or up-referred, alerts the provider if up-referral is required,
and automatically transfers files and schedules appointments as
needed.
Sample Selection and Matching
We conducted a secondary analysis of routinely collected data
from a cohort of patients followed in a routine care setting. As the
intervention had already been implemented, we were unable to
randomize to limit confounding. Instead, we used a quasi-
experimental design in which we matched down-referred patients
(down-referral group) to non-down-referred patients (treatment-
initiation group) to attempt to create similar populations at the
time of eligibility for down-referral. We included all ART patients
down-referred from TLC to Crosby Clinic between 1 February
2008 and 1 January 2009. Down-referred patients were matched
to not down-referred patients 1:3 based on gender, age (18–24.99,
25–29.99, 30–39.99, 40–49.99, and $50 y), time on ART (in 6-
mo intervals), ARV regimen at study eligibility, and CD4 count at
study eligibility (0–99 100–199, 200–349, and $350 cells/mm
3).
Matching was accomplished though propensity scores [10,11]. We
allowed treatment-initiation site patients to be used as a match
more than once, but not within the same 6-mo time interval.
Patients were excluded from both groups if they were (1) down-
referred to a site other than Crosby Clinic, (2) had ,12 mo of
potential follow up after down-referral or down-referral eligibility,
(3) initiated treatment outside TLC, (4) had a non-standard
treatment regimen; or (5) had missing or erroneous medical record
data. In the remainder of this paper, ‘‘study eligibility’’ refers to
eligibility for either group.
Data Collection
Methods for data collection and costing have been described
previously [12]. Taking the provider’s perspective, each study
participant’s electronic medical record was reviewed, and resource
usage data for the 12-mo period following down-referral eligibility
were collected. For down-referred patients who returned to the
treatment-initiation site during the study period (i.e., were up-
referred), resource utilization included resources provided by the
treatment-initiation site. Resources captured included ARVs, non-
ARV medications, laboratory tests, outpatient visits, infrastructure,
equipment and furnishings, data capture, and program manage-
ment. An outpatient visit at the treatment-initiation site included
consultations with both a nurse and a doctor; if a patient also
collected medications, an additional pharmacy cost was added to
the total visit cost. An outpatient visit at the down-referral site was
limited to a consultation with the PHCN, who also dispensed
medications. Utilization of fixed resources (e.g., infrastructure and
administrative staff) for participants who died or were lost to follow
up was prorated based on the number of months the patient
remained in care. Unit costs were estimated in 2009 South African
rand from service provider price lists and financial information
provided by the sites. Costs were converted to US dollars at a rate
of R8.40 to US$1.00.
Data Analysis
Each study participant at both sites was assigned to a single
outcome category on the basis of patient status 12 mo after down-
referral eligibility. Criteria for assigning outcomes were adapted
from previous work in South Africa assessing patient outcomes
12 mo after treatment initiation [12]. To cope with inconsistent
timing of clinic visits and laboratory tests, medical record
information within a 3-mo window on either side of 12 mo (i.e.,
9–15 mo after down-referral eligibility) was used in determining
outcomes, as shown in Table 1.
Using these criteria, outcome assignments were made hierar-
chically, as illustrated in Figure 1. Up-referral—return of a down-
referred patient to the treatment-initiation site for monitoring and
care—was not considered a discrete outcome. Outcomes for up-
referred patients were assigned using the same criteria as for all
other patients, as defined in Table 1, and costs incurred at the
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cost per down-referred patient.
Once an outcome was assigned, we estimated a total cost for
each patient based on all resources utilized during the 12-mo study
period. We estimated an average cost per patient-year in care for
each outcome category by site. The cost-effectiveness of the two
sites was compared on the basis of average cost per patient
remaining in care and responding at the 12-mo point. We created
95% confidence intervals (CIs) around these estimates using
bootstrapping with 10,000 replicates [13].
Results
Sample Selection and Cohort Characteristics
Selection of patients from each site is illustrated in Figure 2, and
study participants are described in Table 2. We enrolled 712 study
participants from the down-referral site and 2,136 patients from
the treatment-initiation site. There was little difference between
the groups in the characteristics on which they were matched.
Down-referred patients excluded because of missing data were
similar to patients in the down-referral group in terms of age, time
on ART, CD4 count, and treatment regimen.
Treatment Outcomes
Treatment outcomes are reported in Table 3. Both groups
showed very good outcomes 12 mo after down-referral eligibility,
with well over 90% of patients remaining in care. The down-
referral site experienced fewer deaths and losses to follow up,
losing just 2% of its patients during the observation period. As a
result, the relative risk of no longer being in care in the down-
referral group was markedly lower than in the treatment-initiation
group (relative risk=0.27, 95% CI 0.15–0.49). The adjusted
hazard ratio was estimated, but it showed no difference from the
relative risk estimate. In total, 122 patients in the down-referral
group (17.1%) were up-referred within the 12-mo period, after an
average of 6.1 mo at the down-referral site. These participants
remained in the down-referral group for this analysis. Most of
them met the criteria for ‘‘in care and responding’’ after up-
referral and are categorized as such in Table 3.
Resource Utilization
Average resource utilization by patients who remained in care
at 12 mo is shown in Table 4, which also provides unit cost
estimates for the resources for which unit cost varied by site. Usage
of viral loads and CD4 counts varied little between the samples.
Down-referred patients made nearly twice as many clinic visits as
patients remaining at the treatment-initiation site, but at a cost per
visit of less than half. Fixed costs were also much lower at the
down-referral site than at the treatment-initiation site.
Costs and Cost-Effectiveness
The average cost per patient by outcome, and the breakdown of
total cost by major cost components for patients who remained in
care and responding at 12 mo, are reported in Table 5. For a
patient who remained in care and responding for the 12 mo
following down-referral eligibility, treatment at the down-referral
site cost an average of US$59 (95% CI US$49–US$70, p,0.001)
per year less than at the treatment-initiation site, a savings of 11%.
The down-referral site spent less on every component of cost
except ARVs. Differences in non-ARV drug and lab test costs can
be attributed to the greater latitude doctors have in prescribing
drugs and diagnostics beyond what is mandated by guidelines.
Despite the larger number of clinic visits per patient-year by down-
referral patients, the down-referral site still saved money on
outpatient visits because of its much lower unit cost per visit.
Using the data in Tables 3 and 5, we estimate that the down-
referral site spends an average of US$509 (95% CI US$500–
US$519) to produce a patient who is in care and responding 1 y
after down-referral, taking into account the resources invested in
those who do not respond, die, or are lost to follow up, and
Table 1. Criteria for assigning HIV treatment outcomes.
Outcome Criteria for Assigning Outcome Comments
Excluded from study Started treatment prior to public rollout Patient initiated ART prior to the South African
national treatment plan launched in April 2004
Outside of study period Down-referred/eligible for down-referral before
1 February 2008 or after 1 January 2009
Less than 12 mo of potential follow up Started ART ,12 mo prior to data collection or transferred
formally to a different site; informal transfers without medical
record notation are recognized as loss to follow up
Non-standard ARV regimen Patient on a regimen that was not part of the
national treatment guidelines during the study
Missing matching data/erroneous data Includes patients who do not have a viral load,
CD4 count, regimen, weight, age, or gender
No longer in care Died Only reported deaths included; deaths never reported
to the site are recognized as loss to follow up
Lost to follow up $3 mo late for last scheduled consultation or medication pickup
In care but not responding Detectable viral load (virologic failure) Viral load .400 copies/ml in month 9–15
If no viral load available, insufficient CD4 change
(immunologic failure)
CD4 decrease of $30% from peak
or #baseline in month 9–15
In care and responding Undetectable viral load Viral load #400 copies/ml in month 9–15
If no viral load available, sufficient CD4 change CD4 within 30% of peak and .baseline in month 9–15
If no viral load or CD4 count available, still in care Default outcome for patients remaining
alive and in care but without laboratory results
doi:10.1371/journal.pmed.1001055.t001
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up-referred. The treatment-initiation site spends an average of
US$602 (95% CI US$592–US$612). For this pair of sites in South
Africa, down-referral to a PHC is the cost-effective strategy for
eligible patients.
Discussion
There is general agreement in the literature and in reports from
international agencies that some combination of task-shifting from
higher to lower level care providers and decentralization from
higher to lower level facilities is essential if targets for HIV/AIDS
treatment access in resource-constrained countries are to be met in
the face of still-rising patient numbers and declining donor budgets
[4]. In this study comparing the outcomes and costs of treatment
provided by PHCNs at a PHC with those of treatment provided
by doctors at a hospital-based clinic, we found that, for those
patients eligible for down-referral, the down-referral site achieved
better outcomes at consistently lower costs than the treatment-
initiation site.
Both sites produced very good outcomes for the patients
sampled. To some extent this is not surprising, as only stable
patients who had been on ART for at least 11 mo were eligible for
the study. The relatively large number of patients who die, are lost
to follow up, or fail treatment in the first year on ART were thus
deliberately excluded. Even considering the strict inclusion
criteria, however, outcomes at the down-referral site, where
almost 95% of patients remained in care, were exceptional.
A major impetus for task-shifting and decentralization, in South
Africa and elsewhere, is cost. There is a clear expectation that
moving treatment to lower level clinical staff and facilities will cost
less than the status quo. In this study, we observed a cost reduction
of roughly 11% per patient-year in care. Although this percentage
may be smaller than hoped for, the scale of the treatment program
in South Africa makes the potential for absolute savings large.
South Africa currently has nearly one million patients on ART
[14]. If even a quarter of these could be down-referred, and if the
cost difference we found is applicable to sites across the country,
the estimated difference in cost of US$59 per patient per year
would result in program-wide savings of more than US$14 million
per year, enough to support an additional 25,000–30,000 patients
on ART per year. Using electronic data from the treatment-
initiation site where we conducted the study, we estimated that
roughly 43% of all patients who initiated ART in the first half of
2008 met eligibility criteria for down-referral by the end of 2009,
suggesting that savings could exceed US$25 million per year.
These savings would offset roughly 10%–15% of the cost of adding
the 400,000 new patients per year called for by the country’s
national plan for achieving universal treatment access [15].
Limitations of the Study
Our study had a number of limitations. It looked at only one
pair of sites, which may or may not be representative of other
facilities in South Africa. Both were high volume, well-resourced,
urban sites in one of South Africa’s wealthier provinces. Because
Figure 1. Decision process for assigning HIV treatment outcomes. Patients were placed in a mutually exclusive patient outcome category
12 mo after study enrolment – no longer in care, in care and responding or in care and not responding. Patient outcomes were defined based on the
patient’s vital status, presence in the clinic, viral load or CD4 count at 12 mo after study enrolment. For those patients alive and in treatment, viral
load was the preferred outcome indicator, but in the absence of viral load CD4 count was used and if neither were available then it was assumed the
patient was in care and responding based on their presence in the clinic. The diagnostic result closest to 12 mo, but within 3 mo (9–15 mo) was used.
doi:10.1371/journal.pmed.1001055.g001
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population was divided into those down-referred and those not down-referred (maintained at the treatment-initiation site). Patients were excludedi f
they (1) had missing matching variables, (2) were on non-standard ARV regimens, (3) had insufficient potential follow-up time, (4) were eligible/down-
referred outside the study period, (5) initiated ART prior to the national rollout, (6) were down-referred to another site (i.e., not the study site), or (7)
were ,18 y old. Those down-referred patients included in the study were matched 1:3 with patients maintained at the treatment-initiation site. DR,
down-referral; TI, treatment-initiation site.
doi:10.1371/journal.pmed.1001055.g002
Table 2. Characteristics of ART patients at the time of eligibility for down-referral to nurse-managed care.
Variable Treatment-Initiation Group Down-Referral Group
Number 2,136 712
Mean age at study eligibility, years (IQR)
a 38.5 (32.7–43.68) 38.5 (33.06–42.03)
Sex, percent female
a 65.5 65.3
Median CD4 count at ART initiation, cells/mm
3 (IQR)
b 94 (36–163) 103 (41–168)
Median CD4 count at study eligibility, cells/mm
3 (IQR)
a 397 (309–521) 404 (318–526)
Mean duration on ART at study eligibility, years (IQR)
a 2.3 (1.8–3.3) 2.3 (1.8–3.3)
ARV regimen at study eligibility (percent)
a
Stavudine–lamivudine–efavirenz 64.8 63.8
Zidovudine–lamivudine–efavirenz 27.1 27.1
Other 8.1 9.1
aThese characteristics were matched between the two samples.
bNote that 15.4% of participants in the treatment-initiation sample and 11.5% in the down-referral sample did not have baseline CD4 counts reported.
IQR, inter-quartile range.
doi:10.1371/journal.pmed.1001055.t002
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located close together, most patients did not face different
obstacles in accessing the sites, such as higher transport costs.
This is unlikely to be the case in many settings. Both sites were
government health facilities and followed the prescribed treatment
regimens and monitoring algorithms as outlined in the national
treatment guidelines. In these respects, the study sites were
comparable to the many public sector treatment sites within South
Africa. Both sites did receive some external donor support,
however, and our findings might not pertain to under-resourced
sites. The generalizability of our findings to other African countries
may also be limited because of the diverse conditions under which
care and treatment are offered across sub-Saharan Africa. For
example, South Africa relies on doctors, rather than clinical
officers, to provide routine care and has access to a wider range of
diagnostics (e.g., viral load tests) than do many other countries.
A well-designed randomized clinical trial usually produces the
most unbiased outcome estimates (internal validity), but may have
a low degree of external validity, or relevance to the real world
[16]. While using observational data generated through routine
practice may have allowed some bias in our study, it also
strengthened the relevance of our findings. In addition, by
matching participants in our study, we reduced the potential for
any strong bias. Still, while we matched down-referred and non-
down-referred patients on known and measured factors affecting
treatment outcomes, there is the potential that our populations
differed with respect to some unmeasured factor. In order to
determine the sensitivity of our results to changes in patient
outcomes as a result of such a factor we varied (decreased) the
proportion of patients in care and responding in the down-referred
arm. The proportion of patients in care and responding would
have to drop from 96% to 77% in this arm, with no changes to the
initiation-site arm, for the costs per patient in care and responding
to be equal. If we take the more likely scenario of equivalent
outcomes as seen in the CIPRA clinical trial [9], the cost per
nurse-managed patient in care and responding would still be lower
than the cost of those managed by doctors ($509 versus $602), and
nurse-managed care would therefore still be the preferred choice.
The study reflects treatment guidelines that were in effect until
2010, including the use of stavudine in first-line treatment. In the
revised guidelines, new ART patients and those experiencing
stavudine toxicities will be prescribed tenofovir. The much greater
tolerability of tenofovir may alter the relative effectiveness of
doctors and nurses in managing ART patients. While we would
expect this to make it even easier for nurses to manage treatment,
we cannot be certain. We also cannot evaluate the extent to which
the relatively low patient volumes seen at the down-referral site
affected the quality of care delivered. Very large down-referral
sites, and those that have exceeded their service delivery capacity,
may achieve poorer patient outcomes than those we observed.
Finally, as has been noted in recent publications, the rate of
reported ‘‘loss to follow up’’ from any one treatment facility may
overstate actual patient attrition from treatment, as many patients
who are reported as lost have actually re-started treatment
somewhere else [17]. If this phenomenon was more common at
the treatment-initiation site in our study than at the down-referral
site, the actual difference in outcomes between our two sites may
be less than we observed.
Table 3. HIV treatment outcomes 12 mo after down-referral eligibility.
Outcome Treatment-Initiation Group (n=1,623) Down-Referral Group (n=540) Relative Risk (95% CI)
a
Total 2,136 (100%) 712 (100%) —
In care and responding 1,912 (89.5%) 680 (95.5%) 1.07 (1.04–1.09)
In care but not responding 91 (4.3%) 20 (2.8%) 0.66 (0.39–1.06)
No longer in care 133 (6.2%) 12 (1.7%) 0.27 (0.15–0.49)
Died 25 (1.2%) 0 (0.0%)
Lost to follow up 108 (5.1%) 12 (1.7%)
aRelative risk of outcome at down-referral site, with treatment-initiation site as reference.
doi:10.1371/journal.pmed.1001055.t003
Table 4. Average resource utilization and selected unit costs for the study sample (n=2,160) over 12 mo from the date of down-
referral eligibility.
Resource Treatment-Initiation Site Down-Referral Site
Average utilization per patient-year in care
Treatment-initiation site visit 4.4 1.5
Down-referral site visit 0.0 5.6
CD4 count 1.6 1.5
Viral load test 1.6 1.4
Unit costs
a
Average cost per outpatient visit, US$ 14 7
Average fixed cost per patient per month, US$ 98 59
aCosts were converted to US dollars at a rate of R8.40 to US$1.00.
doi:10.1371/journal.pmed.1001055.t004
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In addition to the financial cost savings estimated in this study,
transferring patients to nurse-managed, primary-level clinics has
the additional advantage of freeing up the time and resources of
more highly trained doctors and well-equipped facilities to focus
on patients who are not responding to treatment or have other
complications. Task-shifting allows more health care workers to
provide ART care, and this in turn increases the treatment
coverage available to meet the large unmet need. Although South
Africa faces a shortage of both doctors and nurses, the scarcity of
doctors is greater [18], and this scarcity may not be fully reflected
in the salary differential between the two job grades. The financial
cost-effectiveness analysis presented here thus does not capture the
full opportunity costs of the intervention evaluated.
The national treatment guidelines adopted in 2010 allow nurses
to initiate, as well as manage, ART, under a model known as
NIMART (Nurse-Initiated and Managed ART). This policy
change was based on modeled estimates of the cost savings from
task-shifting but with little empirical evidence confirming that
these savings will indeed be realized. This study provides strong
evidence that at least part of the NIMART model—the
management of stable patients by PHCNs—will reduce overall
treatment program costs in South Africa, without compromising
patient outcomes.
Acknowledgments
We thank the staff of the study sites, who helped us to collect and interpret
the data, and the City of Johannesburg and the Gauteng Department of
Health for the participation of its clinics.
Author Contributions
Conceived and designed the experiments: LL AB MPF IS IJ SR. Analyzed
the data: LL AB MPF SR. Wrote the first draft of the paper: LL SR. Wrote
the paper: LL AB MPF BN IJ IS SR. ICMJE criteria for authorship read
and met: LL AB MPF BN IJ IS SR. Agree with the manuscript’s results
and conclusions: LL AB MPF BN IJ IS SR.
References
1. World Health Organization (2008) Task shifting: rational redistribution of tasks
among health workforce teams: global recommendations and guidelines. Geneva:
World Health Organization, Available: http://www.who.int/healthsystems/
TTR-TaskShifting.pdf. Accessed 2 November 2010.
2. Callaghan M, Ford N, Schneider H (2010) A systematic review of task- shifting
for HIV treatment and care in Africa. Hum Resour Health 8: 8. doi:10.1186/
1478-4491-8-8.
3. Bedelu M, Ford N, Hilderbrand K, Reuter H (2007) Implementing
antiretroviral therapy in rural communities: the Lusikisiki model of decentralized
HIV/AIDS care. J Infect Dis 196(Suppl): S464–S468.
4. Fatti G, Grimwood A, Bock P (2010) Better antiretroviral therapy outcomes at
primary healthcare facilities: an evaluation of three tiers of ART services in four
South African provinces. PLoS ONE 5: e12888. doi:10.1371/journal.-
pone.0012888.
5. Humphreys CP, Wright J, Walley J, Mamvura CT, Bailey KA, et al. (2010)
Nurse led, primary care based antiretroviral treatment versus hospital care: a
controlled prospective study in Swaziland. BMC Health Serv Res 10: 229.
6. Bemelmans M, Van Den Akker T, Ford N, Philips M, Zachariah R, et al. (2010)
Providing universal access to antiretroviral therapy in Thyolo, Malawi through
task shifting and decentralization of HIV/AIDS care. Trop Med Int Health 15:
1413–1420. doi:10.1111/j.1365-3156.2010.02649.x.
7. Selke HM, Kimaiyo S, Sidle JE, Vedanthan R, Tierney WM, et al. (2010) Task-
shifting of antiretroviral delivery from health care workers to persons living with
HIV/AIDS: clinical outcomes of a community-based program in Kenya. J Acquir
Immune Defic Syndr 55: 483–490. doi:10.1097/QAI.0b013e3181eb5edb.
8. Sanne IM, Orrell C, Fox MP, Conradie F, Ive P, et al. (2010) Nurse versus
doctor management of HIV-infected patients receiving antiretroviral therapy
(CIPRA-SA): a randomised non-inferiority trial. Lancet 376: 33–40.
9. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, et al. (2009) Long
term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in
urban South Africa: a prospective cohort study. J Int AIDS Soc 12: 38.
doi:10.1186/1758-2652-12-38.
10. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in
observational studies for causal effects. Biometrika 70: 41–55. doi:10.1093/
biomet/70.1.41.
11. Kosanke JL, Bergstralh EJ (2010) Dist [SAS macro]. Rochester (Minnesota):
Division of Biomedical Statistics and Informatics, Mayo Clinic, 2010,
Available: http://mayoresearch.mayo.edu/biostat/sasmacros.cfm. Accessed 9
June 2011.
12. Rosen S, Long L, Sanne IM (2008) The outcomes and outpatient costs of
different models of antiretroviral treatment delivery in South Africa. Trop Med
Int Health 13: 1005–1015. doi:10.1111/j.1365-3156.2008.02114.x.
Table 5. Average cost per patient, by HIV treatment outcome and cost component.
Outcome or Cost Component Cost, in US Dollars
Treatment-Initiation Patients Down-Referral Patients
Outcome, mean (standard deviation)
All patients in group 539 (141) 486 (98)
a
In care and responding 551 (128) 492 (88)
a
In care but not responding 589 (163) 481 (97)
a
No longer in care 330 (147) 175 (103)
a
Cost component, value (proportion of total)
b
Drugs—ARV 237 (43%) 262 (53%)
Drugs—non-ARV 16 (3%) 7 (1%)
Lab tests 120 (22%) 101 (21%)
Outpatient visits 80 (15%) 60 (12%)
Fixed costs 98 (18%) 62 (13%)
Total 551 (100%) 492 (100%)
Costs are given in 2009 US dollars, converted at a rate of R8.40 to US$1.00.
ap,0.001 for difference between treatment-initiation and down-referral patients.
bOnly patients who were still in care and responding at 12 mo were included.
doi:10.1371/journal.pmed.1001055.t005
Doctor- versus Nurse-Managed ART in South Africa
PLoS Medicine | www.plosmedicine.org 8 July 2011 | Volume 8 | Issue 7 | e100105513. Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Boca Raton
(Florida): Chapman and Hall/CRC. 436 p.
14. Joint United Nations Programme on HIV/AIDS (2010) Outlook report 2010.
Geneva: Joint United Nations Programme on HIV/AIDS, Available: http://
data.unaids.org/pub/Outlook/2010/20100713_outlook_report_web_en.pdf.
Accessed 3 October 2010.
15. South African National AIDS Council (2010) National strategic plan 2007–2011: mid
term review 2010. Pretoria: South African National AIDS Council, Available: http://
www.irinnews.org/pdf/Mid_Term_Review_of_the_NSP_(preliminary_report).pdf.
Accessed 7 April 2011.
16. Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005)
Methods for the economic evaluation of health care programmes, 3rd edition.
Oxford: Oxford University Press. 396 p.
17. Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, et al. (2010) Retention
in care among HIV-infected patients in resource-limited settings: emerging
insights and new directions. Curr HIV/AIDS Rep 7: 234–244. doi:10.1007/
s11904-010-0061-5.
18. World Health Organization (2007) Task shifting to tackle health worker
shortages. Geneva: World Health Organization, Available: http://www.who.
int/healthsystems/task_shifting_booklet.pdf. Accessed 12 January 2011.
Doctor- versus Nurse-Managed ART in South Africa
PLoS Medicine | www.plosmedicine.org 9 July 2011 | Volume 8 | Issue 7 | e1001055Editors’ Summary
Background. AIDS has killed more than 25 million people
since 1981, and about 33 million people are now infected
with HIV, the virus that causes AIDS. Because HIV destroys
immune system cells, which leaves infected individuals
susceptible to other infections, early in the AIDS epidemic,
most HIV-infected people died within ten years of infection.
Then, in 1996, antiretroviral therapy (ART), which can keep
HIV in check for many years, became available. For people
living in developed countries, HIV infection became a chronic
condition, but people in developing countries were not so
lucky—ART was prohibitively expensive and so a diagnosis
of HIV infection remained a death sentence in many regions
of the world. In 2003, this situation was declared a global
health emergency, and governments, international agencies,
and funding bodies began to implement plans to increase
ART coverage in developing countries. As a result, nowadays,
more than a third of people in low- and middle-income
countries who need ART are receiving it.
Why Was This Study Done? Unfortunately, shortages of
human resources in developing countries are impeding
progress toward universal ART coverage. In sub-Saharan
Africa, for example, where two-thirds of all HIV-positive
people live, there are too few doctors to supervise all the
ART that is required. Various organizations are therefore
encouraging a shift of clinical care responsibilities for people
receiving ART from doctors to less highly trained, less
expensive, and more numerous members of the clinical
workforce. Thus, in South Africa, plans are underway to
reduce the role of hospital doctors in ART and to increase the
role of primary health clinic nurses. One specific strategy
involves ‘‘down-referring’’ patients whose HIV infection is
under control (‘‘stable ART patients’’) from a doctor-
managed, hospital-based ART clinic to a nurse-managed
primary health care facility. In this observational study, the
researchers investigate the effect of this strategy on
treatment outcomes and costs by retrospectively analyzing
data collected from a cohort (group) of adult patients initially
treated by doctors at the Themba Lethu Clinic in
Johannesburg and then down-referred to a nearby primary
health clinic where nurses supervised their treatment.
What Did the Researchers Do and Find? Patients
attending the hospital-based ART clinic were invited to
transfer to the down-referral site if they had been on ART for
at least 11 months and met criteria that indicated that ART
was controlling their HIV infection. Each of the 712 stable
ART patients who agreed to be down-referred to the primary
health clinic was matched to three patients eligible for
down-referral but not down-referred (2,136 patients), and
clinical outcomes and costs in the patient groups were
compared 12 months after down-referral eligibility. At this
time point, 1.7% of the down-referred patients had died or
had been lost to follow up compared to 6.2% of the patients
who continued to receive hospital-based ART. The average
cost per patient-year for those in care and responding at 12
months was US$492 for down-referred patients but US$551
for patients remaining at the hospital. Finally, the down-
referral site spent US$509 to produce a patient who was in
care and responding one year after down-referral on
average, whereas the hospital spent US$602 for each
responding patient. Thus, the down-referral strategy
(nurse-managed care) was more cost-effective than
continued hospital treatment (doctor-managed care).
What Do These Findings Mean? These findings indicate
that, at least for this pair of study sites, the 12-month
outcomes of stable ART patients who were down-referred to
a primary health clinic were as good as or better than the
outcomes of similar patients who remained at a hospital-
based ART clinic. Moreover, the down-referral strategy saved
11% of costs for patients who remained in care and
responded to treatment and appeared to be cost-effective,
although additional studies are needed to confirm this last
finding. Because this is an observational study (that is,
patients eligible for down-referral were not randomly
assigned to hospital or primary care facility treatment), it is
possible that some unknown factor was responsible for the
difference in outcomes between the two patient groups.
Nevertheless, these results suggest that the down-referral
strategy tested in this study could increase ART capacity and
conserve resources without compromising patient outcomes
in South Africa and possibly in other resource-limited
settings.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
journal.pmed.pmed.1001055.
N This study is further discussed in a PLoS Medicine
Perspective by Ford and Mills
N The US National Institute of Allergy and Infectious Diseases
provides information on HIV infection and AIDS
N HIV InSite has comprehensive information on HIV/AIDS
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in Africa and on universal access to
AIDS treatment (in English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment, including its 2010
progress report (in English, French and Spanish)
N Right to Care, a non-profit organization that aims to deliver
and support quality clinical services in Southern Africa for
the prevention, treatment, and management of HIV,
provides information on down-referral
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